Laurus Labs to increase stake in ImmunoACT to 33.86%
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
For the treatment of Superficial Femoral Artery
The product is expected to be launched in June 2023
Unani Medicine facilities to be upgraded at Hyderabad, Chennai, Lucknow, Silchar and Bengaluru
Continues to Expand its Presence in South India
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
Subscribe To Our Newsletter & Stay Updated